Why the study?
Does the Micra VVIR leadless pacemaker reduce system- or procedure-related major complications compared to transvenous pacemakers in patients requiring de novo ventricular pacing?
Does the Micra VVIR leadless pacemaker reduce system- or procedure-related major complications compared to transvenous pacemakers in patients requiring de novo ventricular pacing?
The Micra leadless pacemaker demonstrated a 48% lower risk of major complications at 12 months compared to historical transvenous pacemakers, with excellent electrical performance through 24 months.
No takes yet. Share an insight, caveat, or question.
May support leadless pacing to lower complications; leaves open randomized confirmation before practice change.
Duray et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: